Claritin Appeals Court Endorses Metabolite Patents, But Not Broad Claims
Executive Summary
Metabolites of known drugs may not receive patent protection through broad compound claims, a D.C. federal appeals court ruled Aug. 1 in the Claritin patent infringement case